Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915589 | Completed Phase 2

• 2 other identifiers: 165532013-000311-25
• Study Type: interventional
• Target: 16
• Locations: 17 countries
• Sites: 58

Brief Summary

This is a study to investigate the potential clinical benefit of refametinib in patients with unresectable or metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages. Approximately 95 patients (15 at Stage 1/ 80 at Stage 2) will be accrued to this study to receive treatment. Stage 2 of the trial will only be conducted if at least 5 out of 15 patients at Stage 1 show at least confirmed partial response (PR) according to modified response evaluation criteria in solid tumors (mRECIST) assessed by central image review. Refametinib is an oral (i.e. taken by mouth) protein kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, refametinib may stop cancer growth. The growth of the tumor may be decreased by preventing these specific proteins from functioning. The primary endpoint (the most meaningful result to be tracked) of this study is based on the rate of response, i.e. the disease getting smaller. The aim is to show that the therapy with refametinib improves the response rate in this RAS mutation patient population.

Conditions

Carcinoma, Hepatocellular

Keywords

Hepatocellular Carcinoma; Mitogen-activated Extracellular-signal-regulated kinase (MEK) inhibitor; Objective tumor response rate (ORR); modified RECIST criteria

Outcome Measures

Primary Outcomes (1)

• Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review

  Approximately 36 months

Secondary Outcomes (11)

• Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review

  Approximately 36 months

• Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators

  Approximately 36 months

• Disease control (central and investigator's assessment)

  Approximately 36 months

• Overall survival

  Approximately 36 months

• Time to radiographic tumor progression (central and investigator's assessment)

  Approximately 36 months

Study Arms (1)

Refametinib (BAY86-9766)

EXPERIMENTAL

For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.

Drug: Refametinib (BAY86-9766)

Interventions

Refametinib (BAY86-9766) DRUG

All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.

Refametinib (BAY86-9766)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Eligibility criteria for RAS mutation testing
• Unresectable or metastatic HCC, confirmed either by histology or clinically according to the American Association for the Study of Liver Disease (AASLD) criteria for cirrhotic patients. For non-cirrhotic patients, histological confirmation is mandatory.
• Male or female ≥18 years of age.
• Eastern Cooperative Oncology Group (ECOG) performance state 0 or 1.
• Life expectancy of at least 12 weeks.
• No prior use of targeted agents, experimental therapy or systemic anti-cancer treatment for HCC (except sorafenib)
• No previous treatment with refametinib(BAY86-9766). Criteria for study treatment eligibility
• Patient must harbor GTPase Kirsten rat sarcoma viral oncogene homolog (KRAS) or Neuroblastoma RAS viral oncogene homolog (NRAS) mutation based on Beads, emulsions, amplification, and magnetic technology, sensitive mutation detection (BEAMing) plasma test.
• Patients must have at least one uni-dimensional measurable lesion by Computed tomography (CT) or Magnetic resonance (MR) according to RECIST 1.1 and mRECIST which is either naïve (not previously treated by local therapy such as surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) or previously treated and has progressed until baseline (both measureable lesion and/or progressed lesion have to be confirmed by central image review of baseline and progression scan).
• ECOG performance status of 0 or 1.
• Liver function status of Child-Pugh Class A.
• Adequate bone morrow, liver, and renal function
• Patient has within normal range cardiac function confirmed by the enrolling clinical institute as measured by echocardiogram or multiple gated acquisition (MUGA) scan.
• Patients who are therapeutically anti-coagulated with an agent such as warfarin or heparin are allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until International normalized ratio (INR) is stable (within Child Pugh class A threshold) based on a measurement at pre-dose, as defined by the local standard of care.

You may not qualify if:

• Any Cancer curatively treated \< 3 years prior to study entry, except cervical carcinoma in situ (CIS), treated basal cell carcinoma, and superficial bladder tumors \[Staging: noninvasive papillary tumor (Ta), CIS carcinoma (Tis) and tumor invades lamina propria (T1)\]
• Subjects who are eligible for surgery, liver transplantation, ablation or transarterial chemoembolization for HCC.
• History of cardiac disease
• Uncontrolled hypertension (systolic blood pressure \[BP\] \>150 mmHg or diastolic blood pressure \> 90 mmHg despite optimal medical management).
• Ongoing infection \> Grade 2 according to National Cancer Institute - Common Toxicity Criteria for Adverse Events version 4.03 (NCI-CTCAE version 4.03) Hepatitis B is allowed if no active replication (defined as abnormal Alanine aminotransferase \[ALT\] \>2x Upper limit normal \[ULN\] associated with Hepatitis B virus \[HBV\] DNA \>20,000 IU/mL) is present. Hepatitis C is allowed if no antiviral treatment is required.
• Known history of, or symptomatic metastatic brain or meningeal tumors (head CT or MR at Screening to confirm the absence of central nervous system \[CNS\] disease if patient had symptoms suggestive or consistent with CNS disease).
• History of interstitial lung disease (ILD).
• History of hepatic encephalopathy.
• History of organ allograft, cornea transplantation will be allowed.
• History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
• Visible retinal pathology as assessed by ophthalmologic exam that was considered a risk factor for RVO or CSR.

Sponsors & Collaborators

• Bayer: lead

Study Sites (58)

Unknown Facility

Washington D.C., District of Columbia, 20007-2197, United States

Location

Unknown Facility

Miami, Florida, 33136, United States

Location

Unknown Facility

Tampa, Florida, 33612, United States

Location

Unknown Facility

New York, New York, 10029, United States

Location

Unknown Facility

Rochester, New York, 14642, United States

Location

Unknown Facility

Graz, 8036, Austria

Location

Unknown Facility

Bruxelles - Brussel, 1070, Belgium

Location

Unknown Facility

Bruxelles - Brussel, 1200, Belgium

Location

Unknown Facility

Charleroi, 6000, Belgium

Location

Unknown Facility

Ghent, 9000, Belgium

Location

Unknown Facility

Leuven, 3000, Belgium

Location

Unknown Facility

Prague, 128 08, Czechia

Location

Unknown Facility

Clermont-Ferrand, 63003, France

Location

Unknown Facility

Créteil, 94010, France

Location

Unknown Facility

Lille, 59037, France

Location

Unknown Facility

Marseille, 13005, France

Location

Unknown Facility

Montpellier, 34059, France

Location

Unknown Facility

Vandœuvre-lès-Nancy, 54511, France

Location

Unknown Facility

Heidelberg, Baden-Wurttemberg, 69120, Germany

Location

Unknown Facility

München, Bavaria, 81377, Germany

Location

Unknown Facility

Hanover, Lower Saxony, 30625, Germany

Location

Unknown Facility

Essen, North Rhine-Westphalia, 45136, Germany

Location

Unknown Facility

Mainz, Rhineland-Palatinate, 55131, Germany

Location

Unknown Facility

Berlin, 13353, Germany

Location

Unknown Facility

Shatin, Hong Kong

Location

Unknown Facility

Budapest, 1062, Hungary

Location

Unknown Facility

Debrecen, 4032, Hungary

Location

Unknown Facility

Milan, Lombardy, 20089, Italy

Location

Unknown Facility

Milan, Lombardy, 20133, Italy

Location

Unknown Facility

Kashiwa-shi, Chiba, 277-8577, Japan

Location

Unknown Facility

Kobe, Hyōgo, 650-0017, Japan

Location

Unknown Facility

Moriguchi, Osaka, 570-8507, Japan

Location

Unknown Facility

Osaka, Osaka, 541-8567, Japan

Location

Unknown Facility

Osakasayama-shi, Osaka, 589-8511, Japan

Location

Unknown Facility

Sunto, Shizuoka, 411-8777, Japan

Location

Unknown Facility

Shimotsuke, Tochigi, 329-0498, Japan

Location

Unknown Facility

Chuo-ku, Tokyo, 104-0045, Japan

Location

Unknown Facility

Osaka, 543-8555, Japan

Location

Unknown Facility

Shizuoka, 420-8527, Japan

Location

Unknown Facility

Auckland, 1023, New Zealand

Location

Unknown Facility

Busan, 49241, South Korea

Location

Unknown Facility

Daegu, 41404, South Korea

Location

Unknown Facility

Seoul, 03080, South Korea

Location

Unknown Facility

Seoul, 05505, South Korea

Location

Unknown Facility

Seoul, 135-710, South Korea

Location

Unknown Facility

Santiago de Compostela, A Coruña, 15706, Spain

Location

Unknown Facility

Barcelona, Catalonia, 08035, Spain

Location

Unknown Facility

Alicante, 03010, Spain

Location

Unknown Facility

Pontevedra, 36071, Spain

Location

Unknown Facility

Valencia, 46010, Spain

Location

Unknown Facility

Geneva, Canton of Geneva, 1211, Switzerland

Location

Unknown Facility

Bern, 3010, Switzerland

Location

Unknown Facility

Kaohsiung City, 8330, Taiwan

Location

Unknown Facility

Tainan, 704, Taiwan

Location

Unknown Facility

Bangkok, 10210, Thailand

Location

Unknown Facility

Bangkok, 10330, Thailand

Location

Unknown Facility

Bangkok, 10700, Thailand

Location

Unknown Facility

Birmingham, West Midlands, B15 2TT, United Kingdom

Location

Related Links

• Click here to find results for studies related to Bayer Healthcare products.
• Click here to find information about studies related to Bayer Healthcare products conducted in Europe.

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Interventions

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2013
• First Posted: August 5, 2013
• Study Start: September 16, 2013
• Primary Completion: October 8, 2014
• Study Completion: October 8, 2014
• Last Updated: April 8, 2021

Record last verified: 2021-04

Locations

IT (2); HU (2); JP (10); TH (3); CZ (1); HK (1); CH (2); BE (5); KR (5); FR (6); TW (2); US (5); NZ (1); DE (6); ES (5); GB (1); AU (1)